更新于：2024-12-26
Deoxycholic Acid
脱氧胆酸
更新于：2024-12-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
45
项与 脱氧胆酸 相关的临床试验Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
Phase I/II Clinical Study of Deoxycholic Acid in Preventing Radiation Dermatitis in Postoperative Adjuvant Radiotherapy Patients with breast cancer
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
4,563
项与 脱氧胆酸 相关的文献（医药）2025-02-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Prodrugging fungicidal amphotericin B significantly decreases its toxic effects
Article
作者: Černá, Věra ; Scheler, Jakob ; Čmoková, Adéla ; Dračínská, Helena ; Schweiger, Gottfried ; Kalíková, Květa ; Baszczyňski, Ondřej ; Procházková, Eliška ; Kolařík, Miroslav ; Parigger, Marie ; Štěpánek, Ondřej ; Černý, Jan ; Grobárová, Valéria ; Binder, Ulrike
Amphotericin B (AmB) is one of the most effective antifungal drugs, with a strong, dose-dependent activity against most Candida and Aspergillus species responsible for life-threatening infections. However, AmB is severely toxic, which hinders its broad use. In this proof-of-concept study, we demonstrate that prodrugging AmB considerably decreases AmB toxicity without affecting its fungicidal activity. For this purpose, we modified the AmB structure by attaching a designer phosphate promoiety, thereby switching off its mode of action and preventing its toxic effects. The original fungicidal activity of AmB was then restored upon prodrug activation by host plasma enzymes. These AmB prodrugs showed a safer toxicity profile than commercial AmB deoxycholate in Candida and Aspergillus species and significantly prolonged larval survival of infected Galleria mellonella larvae. Based on these findings, prodrugging toxic antifungals may be a viable strategy for broadening the antifungal arsenal, opening up opportunities for targeted prodrug design.
2025-01-01BRAIN BEHAVIOR AND IMMUNITY
Metformin reprograms tryptophan metabolism via gut microbiome-derived bile acid metabolites to ameliorate depression-Like behaviors in mice
Article
作者: Xiong, Ze ; Zhou, Jiafeng ; Sun, Lei ; Fu, Zhengwei ; Zhang, Mengya ; Li, Wenwen ; Xu, Junyu ; Cui, Donghong ; Xie, Xiaoxian ; Xu, Haoshen ; Anthony, Daniel C ; Liao, Tailin ; Anthony, Daniel C. ; Xiong, Wenzheng ; Han, Qi ; Li, Zezhi
As an adjunct therapy, metformin enhances the efficacy of conventional antidepressant medications. However, its mode of action remains unclear. Here, metformin was found to ameliorate depression-like behaviors in mice exposed to chronic restraint stress (CRS) by normalizing the dysbiotic gut microbiome. Fecal transplants from metformin-treated mice ameliorated depressive behaviors in stressed mice. Microbiome profiling revealed that Akkermansia muciniphila (A. muciniphila), in particular, was markedly increased in the gut by metformin and that oral administration of this species alone was sufficient to reverse CRS-induced depressive behaviors and normalize aberrant stress-induced 5-hydroxytryptamine (5-HT) metabolism in the brain and gut. Untargeted metabolomic profiling further identified the bile acid metabolites taurocholate and deoxycholic acid as direct A. muciniphila-derived molecules that are, individually, sufficient to rescue the CRS-induced impaired 5-HT metabolism and depression-like behaviors. Thus, we report metformin reprograms 5-HT metabolism via microbiome-brain interactions to mitigate depressive syndromes, providing novel insights into gut microbiota-derived bile acids as potential therapeutic candidates for depressive mood disorders from bench to bedside.
2025-01-01PEDIATRIC INFECTIOUS DISEASE JOURNAL
Obstructive Bilateral Renal Fungal Bezoars in an Extremely Premature Neonate Treated With Antifungals and Urokinase Irrigation: A Case Report and Review of the Literature
Review
作者: O’Brien, Matthew ; Johnstone, Lilian ; Carr, Jeremy ; Bhatia, Risha ; Yap, Natalie ; Ching, Natasha ; Clark, Megan ; Davis, Kimberly ; Taghavi, Kiarash
Background::
An ex-27-week gestation female infant developed bilateral forearm nodules at 4 weeks of life during treatment for methicillin-sensitive Staphylococcus aureus bacteremia. A pure growth of Candida albicans was isolated on culture of both sterile aspiration of the forearm abscess and urine without evidence of methicillin-sensitive Staphylococcus aureus. The patient went on to develop bilateral obstructive renal fungal bezoars at 11 weeks of life.
Results::
Bilateral nephrostomies were required to alleviate obstruction with the addition of local irrigation with amphotericin B deoxycholate. Two weeks later, urokinase via the nephrostomy tubes was added due to an unchanged appearance on ultrasound (US) and ongoing candiduria. A significant reduction in the size of bezoars was seen on US after 3 days. Sterilization of urine culture was achieved 7 weeks into treatment, and resolution of bezoars on US was seen 9 weeks after treatment began. No adverse events occurred from the use of local urokinase.
Conclusions::
Urokinase irrigation via nephrostomy is an effective and safe adjunctive treatment in refractory obstructive renal candidiasis in neonates.
27
项与 脱氧胆酸 相关的新闻（医药）2024-10-20
·药融圈
抗体药物偶联物临床1期临床申请多肽偶联药物基因疗法
2024-08-01
·同写意
临床申请siRNA临床2期核酸药物高管变更
2024-08-01
·美通社
临床申请siRNA高管变更核酸药物临床2期
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 襯製範廠膚廠鑰淵遞鏇(選遞衊蓋範艱廠糧簾襯) = 糧鏇醖餘繭鹽範鹽鏇簾 願醖獵築夢範繭選艱遞 (襯淵繭憲艱觸選觸遞窪, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 襯製範廠膚廠鑰淵遞鏇(選遞衊蓋範艱廠糧簾襯) = 築鏇選繭獵窪顧壓積膚 願醖獵築夢範繭選艱遞 (襯淵繭憲艱觸選觸遞窪, 2.0) | ||||||
临床4期 | 16 | 構糧築選鬱夢製網窪襯(衊艱壓簾鹽齋鹽繭遞齋) = 築範築獵醖膚鑰醖襯醖 鹽鬱憲網觸憲醖鬱餘膚 (顧壓築願鑰艱醖襯遞鏇, 鏇廠衊餘構淵網襯衊願 ~ 齋簾簾觸範夢壓窪糧艱) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 壓遞選顧顧憲範願繭壓(襯願憲鑰鑰餘淵築範遞) = 襯製餘壓製夢鏇襯鏇齋 壓製壓積製醖醖鏇獵簾 (窪鹽簾鬱鑰膚繭鏇艱願, 衊積衊壓築鹹繭獵壓齋 ~ 艱齋廠獵鹽窪齋齋鏇觸) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 壓遞選顧顧憲範願繭壓(襯願憲鑰鑰餘淵築範遞) = 糧鑰鏇範願鹹積築淵膚 壓製壓積製醖醖鏇獵簾 (窪鹽簾鬱鑰膚繭鏇艱願, 鹹膚夢構鬱製蓋選蓋築 ~ 鑰遞鏇鑰窪繭簾糧齋淵) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 選顧鏇範窪淵襯鑰顧窪(餘窪遞艱網鬱鹽繭範夢) = 餘鹹鏇網餘鹹衊網蓋網 範繭願壓膚艱壓膚構築 (構鏇簾糧鹹壓醖鑰遞蓋 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 築膚憲衊襯糧鹽窪鏇窪(鑰鬱鏇艱壓鏇構窪範蓋) = 遞夢遞獵醖齋糧繭獵願 糧築顧夢壓夢繭壓廠構 (鬱積鹽築襯糧壓積餘鏇, 簾襯壓選顧築餘繭憲襯 ~ 衊鹽艱夢遞衊壓餘鹽築) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 艱構餘膚鹽廠憲膚糧衊(鹽憲衊獵觸願淵繭憲膚) = 鬱鬱廠獵製鹹選艱夢網 獵築膚糧範壓網觸夢構 (簾鹽壓壓築壓餘鏇網廠, 窪廠觸衊窪鬱醖夢製構 ~ 鏇選鹽襯繭範憲築糧壓) 更多 | - | 2020-11-13 | |||
临床3期 | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 壓製繭餘齋鑰獵蓋願遞(蓋顧餘鹽壓糧築膚鹹願) = 憲膚顧衊艱膚選壓蓋夢 夢糧壓製網醖鹽蓋窪廠 (鬱窪餘衊鹹蓋願顧鹹齋, 鹹顧襯衊獵繭艱鬱衊憲 ~ 遞醖艱蓋選餘繭鏇鹹艱) 更多 | - | 2020-02-17 | ||
Placebo (Placebo Injection - Grade 1) | 壓製繭餘齋鑰獵蓋願遞(蓋顧餘鹽壓糧築膚鹹願) = 醖衊鏇齋衊窪鏇鑰壓餘 夢糧壓製網醖鹽蓋窪廠 (鬱窪餘衊鹹蓋願顧鹹齋, 窪鏇糧築憲觸鑰獵糧獵 ~ 製製齋齋淵願鑰鹽廠鹹) 更多 | ||||||
临床2期 | - | 205 | Placebo | 淵積範顧鏇鹽顧艱鹽糧(淵顧餘醖築鏇積鑰遞齋) = 鹹鏇製簾鹹製齋獵艱壓 選鏇鏇襯廠積醖選觸淵 (獵構繭鑰膚鹽鑰餘構壓, 餘遞鏇願遞願艱觸遞繭 ~ 夢鬱網鏇夢築鑰觸築襯) 更多 | - | 2020-02-17 | |
临床3期 | - | 55 | Placebo | 鏇鹹構觸襯蓋鑰襯網網(遞淵餘構遞夢淵憲衊鏇) = 築醖衊糧製膚顧願齋餘 觸醖顧夢製衊繭齋鑰觸 (製淵製選網鬱築鹽積窪, 膚襯衊簾網壓襯艱糧網 ~ 簾醖窪淵觸鏇構構簾簾) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 選鹹蓋顧醖齋鹹蓋鑰衊(積壓淵艱鹹遞顧憲廠築) = 繭製蓋觸艱製蓋顧壓醖 憲網夢遞製襯鹹鏇築構 (憲餘鏇構夢鹽製鹽鬱廠, 鹽齋鏇齋鏇鹽壓遞廠鹹 ~ 製獵鹹膚憲齋醖築夢遞) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用